Intellia Therapeutics (NTLA) Tops Q2 EPS by 5c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.98), $0.05 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $11.99 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• D-Wave Quantum (QBTS) call put ratio 5.3 calls to 1 put with a focus on July 26 and 30 calls as share price up 6.9%
• TWO Announces Adjournment of Special Meeting